First Light Acquisition Group, Inc. entered into a business combination transaction with Calidi Biotherapeutics, Inc. through a merger agreement. Shareholders have the right to redeem their Class A Common Stock for approximately $10.49 per share. The filing contains forward-looking statements and lists various risks and uncertainties related to the business combination.